Mainz Biomed (MYNZ) announced a collaboration with CARE diagnostica Laborreagenzien, CARE. CARE is currently working with more than 15 statutory health insurance companies as part of special online-based screening concepts based on the widely used fecal immuniochemical test. In cooperation with Mainz Biomed, the range of services for risk groups can now be expanded to include the ColoAlert test
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed reviews accomplishments for first half of 2025
- Mainz Biomed secures public funding to advance pancreatic cancer screening test
- Promising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy Rating
- Mainz initiates feasibility study of biomarker panel in PancAlert project
- Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting